Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 8/20 | 0.43 |
| ▸ | PGK1 | P00558 | 3/20 | 0.42 |
| ▸ | PGK2 | P07205 | 3/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | CDC14B | O60729 | 1/20 | 0.40 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890733 | 0.79 | PGK1 (0.42) | PTPN1PGK1PGK2PTPRCCDC14B | |
| SCHEMBL1069340 | 0.75 | NOTUM (0.33) | — | |
| SCHEMBL3735747 | 0.72 | PGK1 (0.52) | PTPN1PTPN2PGK1PGK2 | |
| SCHEMBL5507197 | 0.72 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL3739229 | 0.70 | PTPN1 (0.51) | PTPN1PTPN2PGK1PGK2PTPRC | |
| SCHEMBL5499124 | 0.70 | PGK1 (0.71) | PTPN1PTPN2PGK1PGK2PTPRC | |
| SCHEMBL5499845 | 0.69 | PTPN1 (0.51) | PTPN1PTPN2PGK1PGK2PTPRC | |
| SCHEMBL3738171 | 0.69 | PTPN1 (0.50) | PTPN1PTPN2PGK1PGK2PTPRC | |
| SCHEMBL3737925 | 0.69 | PTPN1 (0.70) | PTPN1PTPN2PGK1PGK2 | |
| SCHEMBL3693116 | 0.67 | CA2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786421-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | claimed |
| WO-2006017124-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1786421-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006017124-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | PTPN1 13/4885PTPN2 27/4885PGK1 160/4885 |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | PTPRO, PTPRG, PTPN1 | PTPN1 3/4885PTPN2 24/4885PGK1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.